Meeting
2019 ASCO Annual Meeting
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy: Interim safety and efficacy results from the phase II RAMIRIS Study (AIO-STO-0415) of the German Gastric Group at AIO.
Authors
Sylvie Lorenzen
Klinikum Rechts der Isar der TU München, Munich, Germany
Sylvie Lorenzen , Peter C. Thuss-Patience , Claudia Pauligk , Eray Goekkurt , Thomas Jens Ettrich , Florian Lordick , Michael Stahl , Peter Reichardt , Martin Soekler , Daniel Pink , Stephan Probst , Hana Algül , Axel Hinke , Thorsten Oliver Goetze , Salah-Eddin Al-Batran
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT03081143
Citation
J Clin Oncol 37, 2019 (suppl; abstr 4023)
DOI
10.1200/JCO.2019.37.15_suppl.4023
Abstract #
4023
Poster Bd #
128
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel: Results from the phase II RAMIRIS Study of the AIO.
First Author: Sylvie Lorenzen
Poster
2018 ASCO Annual Meeting
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy – the RAMIRIS Study.
First Author: Sylvie Lorenzen
Poster
2021 ASCO Annual Meeting
Phase II trial of docetaxel and ramucirumab combination therapy as second-line treatment in patients with metastatic or advanced gastric cancer (HGCSG1903).
First Author: Rika Saito
Poster
2019 Gastrointestinal Cancers Symposium
HGCSG 1603: Phase II study of ramucirumab and irinotecan combination therapy as second-line treatment in patients with metastatic or advanced gastric cancer.
First Author: Atsushi Ishiguro